[Oral vaccines against poliomyelitis and vaccination-related paralytic poliomyelitis in Germany. Do we need a new immunization strategy?].
Oral vaccination against poliomyelitis, which was carried out worldwide, lead to eradication of poliomyelitis in the United States, in South America and parts of Europe; in other parts of the world, paralytic poliomyelitis is still a severe risk of health. In those countries where poliomyelitis has been eradicated, it is presently discussed whether the vaccination schedules should be changed to an inactivated polio vaccine (IPV), as in polio-free countries only cases of paralytic poliomyelitis after vaccinations have been reported. Behringwerke's data from a 30-year period of analysing adverse drug reaction reveal the following: using the trivalent oral polio vaccine (OPV), based on WHO case definition, the risk for vaccine-associated paralytic poliomyelitis with permanent damage is approximately 1 case for 4.5 million vaccinations (0.22 per million) in vaccinees, and approximately 1 case for 11 million (0.09 per million) in contact persons. This low risk is in line with the data ascertained worldwide.
Fescharek
R
R
Abteilung für Arzneimittelsicherheit, Chiron Behring GmbH & Co, Marburg, Deutschland.
Arras-Reiter
C
C
Arens
E R
ER
Quast
U
U
Maass
G
G
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D005260:Female; D005858:Germany / Q000453:epidemiology; D006801:Humans; D008297:Male; D010243:Paralysis / Q000139:chemically induced* / Q000453:epidemiology; D011051:Poliomyelitis / Q000453:epidemiology / Q000276:immunology* / Q000517:prevention & control; D011055:Poliovirus Vaccine, Oral / Q000009:adverse effects*; D012703:Serotyping
D011055:Poliovirus Vaccine, Oral
Schluckimpfung gegen Poliomyelitis und impfassoziierte paralytische Poliomyelitis in Deutschland. Brauchen wir eine neue Impfstrategie?